Clinical Trial Update: Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients

View source ↗

Summary

A clinical trial evaluating an early predictor of trastuzumab-related cardiotoxicity in breast cancer patients has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: National Guard Health Affairs | Conditions: Breast Cancer | Status: SUSPENDED